Sustainability | May 20, 2022
Pharma companies with ESG more valuable say investors
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
